Phreesia, Inc. (NYSE:PHR) SVP Sells $14,840.00 in Stock

Phreesia, Inc. (NYSE:PHR) SVP David Linetsky sold 500 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $29.68, for a total value of $14,840.00. Following the transaction, the senior vice president now owns 230,771 shares of the company’s stock, valued at $6,849,283.28. This trade represents a 0.22 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

David Linetsky also recently made the following trade(s):

• On Monday, January 27th, David Linetsky sold 11,685 shares of Phreesia stock. The shares were sold at an average price of $27.48, for a total value of $321,103.80.
• On Wednesday, December 18th, David Linetsky sold 24 shares of Phreesia stock. The shares were sold at an average price of $25.38, for a total value of $609.12.
• On Monday, December 16th, David Linetsky sold 35 shares of Phreesia stock. The shares were sold at an average price of $24.88, for a total value of $870.80.
• On Wednesday, December 11th, David Linetsky sold 11,853 shares of Phreesia stock. The shares were sold at an average price of $24.85, for a total value of $294,547.05.

Phreesia Stock Performance

NYSE:PHR traded down $0.53 during mid-day trading on Friday, hitting $28.47. The company’s stock had a trading volume of 306,682 shares, compared to its average volume of 388,179. Phreesia, Inc. has a 1 year low of $17.07 and a 1 year high of $29.90. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of -19.37 and a beta of 0.94. The business’s fifty day moving average is $24.98 and its two-hundred day moving average is $23.28.

Phreesia (NYSE:PHR) last posted its quarterly earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The company had revenue of $106.80 million for the quarter, compared to analyst estimates of $106.33 million. During the same period in the prior year, the company earned ($0.58) earnings per share. The firm’s revenue was up 16.6% on a year-over-year basis. Analysts anticipate that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Institutional Investors Weigh In On Phreesia

Several hedge funds have recently modified their holdings of PHR. R Squared Ltd purchased a new stake in shares of Phreesia during the 4th quarter worth about $30,000. International Assets Investment Management LLC boosted its stake in shares of Phreesia by 2,179.7% during the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock worth $33,000 after acquiring an additional 1,395 shares in the last quarter. Venturi Wealth Management LLC purchased a new stake in shares of Phreesia during the 4th quarter worth about $76,000. XTX Topco Ltd purchased a new stake in shares of Phreesia during the 3rd quarter worth about $247,000. Finally, Hsbc Holdings PLC acquired a new position in shares of Phreesia during the 2nd quarter worth about $301,000. 92.10% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on PHR shares. Piper Sandler reissued an “overweight” rating and issued a $33.00 price objective (up previously from $31.00) on shares of Phreesia in a research note on Wednesday. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and boosted their price objective for the stock from $24.00 to $32.00 in a research note on Wednesday, January 8th. Truist Financial boosted their price objective on shares of Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Citigroup boosted their price objective on shares of Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Finally, KeyCorp upped their price target on Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 8th. Thirteen investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $31.15.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.